XeroThera has developed breakthrough technologies for tissue engineering and the controlled and targeted delivery of drugs and biological molecules. The technology is the result of twenty years of fundamental studies on sol gel processed, nanoporous, oxide-based materials in academic laboratories at the University of Pennsylvania, Philadelphia.
XeroThera’s unique delivery concepts make it possible to treat conditions that currently defy solutions. It has formulated a pipeline of product concepts that address the prevention and treatment of surgical infections, bone infections, and resistant (“MRSA”) infection; it can also develop tissue engineering scaffolds, and address surgical pain treatment and diabetes wound treatment.
Jonathan Garino, MD, MBA
Member, Board of Directors
Jonathan Garino is a practicing physician, and obtained the M.B.A. degree. He currently is a Clinical Professor of Orthopedic Surgery at Thomas Jefferson Medical College, Philadelphia, is the former director of the Adult Reconstruction Center at the Hospital of the University of Pennsylvania, Philadelphia. He is a national and international expert in hip and knee replacements having participated in numerous scientific studies including 6 IDE trials for ceramic bearings, contributing significantly to bringing this technology to the US market.
Edwin H. Ruzinsky, CPA, CMC
Member, Board of Directors
Mr. Ruzinsky served for many years as Partner at Deloitte Consulting LLC as the firm’s National Director-Media Industry Services. Notably, Mr. Ruzinsky has served on many Corporate Boards, and as Chairman of Holy Name Medical Center in Teaneck, NJ. Additionally, Mr. Ruzinsky is co-author of the Manual of Accounting for Magazine Publishers, has lectured extensively throughout these industries, and is also a recognized expert witness in these areas.
Microparticle for surgical use
Universal, injectable nanoparticle, formulated to treat MRSA
Regulatory pathway (US): Qualified Infectious Disease Product (QIDP)
> Eligible for fast track designation
> Priority review for marketing applications
> Additional 5 years exclusivity granted at time of approval
Micron thin films on implants for continuous local delivery of bactericidal molecules
Unique product concept for strategic partnering
Extensive preclinical studies as a basis for regulatory review
Focus on product with short duration to market (XeroSyn™)
Control core technology
Develop manufacturing capabilities
Advance XeroSyn™ towards the clinic; generate sales
Develop strategic partnerships with a large company from
> the device field (XeroSyn™, XeroMicron™)
> the pharmaceutical/ biotech field (XeroDuo™)
Leverage patent portfolio
Establish presence in both US and Europe